GREY:IMVIQ - Post by User
Post by
QM45on Jun 02, 2019 10:22am
160 Views
Post# 29792156
Re: ASCO Investor Webcast
Re: ASCO Investor WebcastListened to the call this morning. There were lots of analyst questions at the end, I encourage all to listen. Solid and informative. This cohort is heavliy pretreated with 5.3 lines of treatment and 93% platinum resistant vs 3.9 lines and 60% platinum resistant in 1B Epacadostat study.
They are showing same pattern of disease control as phase 1B, but in more difficult population and in monotherapy.
1b is prooving to be long lasting, with one patient who switched to monotherapy at 30 months plus (see the slides)
It's all lining up nicely for FDA meeting later this year, they just need to enroll the other 9 patients for monotherapy ASAP, which they clearly know and are pursuing.
Also, looks like they will have 10 long term patients at the Keytruda update, which should be very exciting in a week's time. Look forward to that update, should be a game changer.
Overall, very happy with the progress, I like the momentum build up, glad I loaded up in the last two months.